Effect of ranibizumab on the efficacy of vitrectomy in patients with PDR

Abstract

AIM:To investigate the clinical effect of ranibizumab assisted 25G vitrectomy for proliferative diabetic retinopathy(PDR).METHODS: Totally 120 patients(120 eyes)from our hospital from October 2014 to November 2017 were selected as subjects, and randomly divided into 2 groups. Sixty patients(60 eyes)in the conventional group were treated with 25G vitrectomy alone. Sixty patients(60 eyes)in the study group were treated with ranibizumab adjuvant 25G vitrectomy. The patients were followed up for 6mo. The duration of operation, intraoperative and postoperative conditions, postoperative complications, and the BCVA, intraocular pressure, central area of the macula in preoperative and postoperative 6mo were compared.RESULTS: The average duration of surgery in the study group was significantly lower than that in the conventional group(t=5.727, PPvs 16.7%, χ2=4.227, Pt=3.362, 2.486, 8.028, all PCONCLUSION: PDR patients treated with ranibizumab-assisted 25G vitrectomy can effectively shorten the operation time, improve macular edema, reduce the incidence of postoperative bleeding and complications, and be safe and reliable.

Keywords

• ranibizumab
• vitrectomy
• proliferative diabetic retinopathy